🔥🐔 BizChicken 🐔🔥

Companies Similar to EyeGate Pharmaceuticals, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Gain Therapeutics, Inc.

Gain Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Site-Directed Enzyme Enhancement Therapy platform

Gain Therapeutics, Inc. is a biotechnology company developing therapies for diseases caused by protein misfolding, focusing on rare genetic diseases and neurological disorders. It utilizes its proprietary technology to discover and develop molecules targeting misfolded proteins.

Tags: allosteric regulation, biotechnology, neurological disorders, protein misfolding, rare genetic diseases

Symbol: GANX

Recent Price: $2.18

Industry: Biotechnology

CEO: Mr. Gene Mack M.B.A.

Sector: Healthcare

Employees: 29

Address: 4800 Montgomery Lane, Bethesda, MD 20814

Phone: 301 500 1556

Last updated: 2024-12-31

Eyenovia, Inc.

Eyenovia, Inc. logo
Market Cap: Lowest
Employees: Lowest

Optejet

Eyenovia, Inc. is focused on developing therapeutic solutions for ophthalmic conditions using its proprietary microdose array print platform and Optejet delivery system. It targets conditions like progressive myopia, presbyopia, and mydriasis.

Tags: Optejet, microdosing, mydriasis, myopia, ophthalmic, pharmaceuticals, presbyopia, therapeutics

Symbol: EYEN

Recent Price: $0.11

Industry: Biotechnology

CEO: Mr. Michael M. Rowe

Sector: Healthcare

Employees: 57

Address: 295 Madison Avenue, New York, NY 10017

Phone: 917 289 1117

Leadership

  • Charles Mather, Chairman of the Board
  • Ellen Strahlman, MD, MS, Independent Director
  • Sean Ianchulev, MD, MPH, Director
  • Michael Geltzeiler, Independent Director
  • Rachel Jacobson, Independent Director
  • Ram Palanki, PharmD, Independent Director
  • Michael Rowe, Director

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Glaukos Corporation

Glaukos Corporation logo
Market Cap: Highest
Employees: Medium

i Stent, i Stent inject, i Stent inject W, i Stent Infinite, i Dose TR

Glaukos Corporation is a medical technology and pharmaceutical company developing therapies for glaucoma, corneal disorders, and retinal diseases. It offers micro-bypass stents and injectable implants intended to improve intraocular treatment.

Tags: corneal disorders, glaucoma treatment, i Dose TR, i Stent, medical technology, ophthalmic, pharmaceutical, retinal diseases

Symbol: GKOS

Recent Price: $149.51

Industry: Medical - Devices

CEO: Mr. Thomas William Burns

Sector: Healthcare

Employees: 907

Address: 229 Avenida Fabricante, San Clemente, CA 92672

Phone: 949 367 9600

Last updated: 2024-12-31

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. logo
Market Cap: High
Employees: Low

APG777, APG808, APG990, APG222

Apogee Therapeutics, Inc. is a biotechnology company developing biologics for the treatment of atopic dermatitis, COPD, and related inflammatory and immunology conditions. Founded in 2022 and based in Waltham, Massachusetts.

Tags: COPD, atopic dermatitis, biologics, biotechnology, clinical stage, immunology, inflammatory

Symbol: APGE

Recent Price: $44.64

Industry: Biotechnology

CEO: Dr. Michael Thomas Henderson M.D.

Sector: Healthcare

Employees: 91

Address: 221 Crescent Street, Waltham, MA 02453

Phone: 650-394-5230

Last updated: 2024-12-31

Beam Therapeutics Inc.

Beam Therapeutics Inc. logo
Market Cap: High
Employees: Medium

precision genetic medicines

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.

Tags: Glycogen Storage Disease Type Ia, beta thalassemia, biotechnology, collaboration, genetic medicine, sickle cell disease

Symbol: BEAM

Recent Price: $25.28

Industry: Biotechnology

CEO: Mr. John M. Evans M.B.A.

Sector: Healthcare

Employees: 472

Address: 238 Main Street, Cambridge, MA 02142

Phone: 857 327 8775

Last updated: 2024-12-31

Cogent Biosciences, Inc.

Cogent Biosciences, Inc. logo
Market Cap: Medium
Employees: Low

CGT9486

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.

Tags: biotechnology, genetically defined diseases, precision therapies, tyrosine kinase inhibitor

Symbol: COGT

Recent Price: $7.67

Industry: Biotechnology

CEO: Mr. Andrew R. Robbins M.B.A.

Sector: Healthcare

Employees: 164

Address: 200 Cambridge Park Drive, Cambridge, MA 02140

Phone: 617 945 5576

Last updated: 2024-12-31

Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Lowest

Biorphen, Carglumic Acid, Rezipres, Alkindi Sprinkle, EPRONTIA, Alaway Preservative Free

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for rare diseases, with a portfolio including treatments like Biorphen, Carglumic Acid, and others for various indications.

Tags: Alaway Preservative Free, Alkindi Sprinkle, Biorphen, Carglumic Acid, EPRONTIA, Pharmaceuticals, Rare Diseases, Rezipres

Symbol: ETON

Recent Price: $13.03

Industry: Biotechnology

CEO: Mr. Sean E. Brynjelsen

Sector: Healthcare

Employees: 30

Address: 21925 West Field Parkway, Deer Park, IL 60010-7208

Phone: 847 787 7361

Last updated: 2024-12-31

Evoke Pharma, Inc.

Evoke Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

Gimoti

Evoke Pharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for gastroenterological disorders, primarily targeting symptoms of diabetic gastroparesis with its product Gimoti.

Tags: drug development, gastroenterology, gastroparesis, healthcare, pharmaceutical

Symbol: EVOK

Recent Price: $4.77

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Matthew J. D'Onofrio MBA

Sector: Healthcare

Employees: 4

Address: 420 Stevens Avenue, Solana Beach, CA 92075

Phone: 858 345 1494

Leadership

  • Matthew J. D’Onofrio, Chief Executive Officer
  • Mark Kowieski, CPA, Chief Financial Officer
  • Marilyn R. Carlson, D.M.D., M.D., Chief Medical Officer
  • Chris Quesenberry, Chief Commercial Officer
  • Cam L. Garner, Chairman
  • Todd C. Brady, M.D., Ph.D., Chief Executive Officer, President, and Director
  • Malcolm R. Hill, Pharm.D., Chief Development Officer
  • Kenneth J. Widder, M.D., Member of Board of Directors
  • Vickie W. Reed, Member of Board of Directors
  • David A. Gonyer, R.Ph., Member of Board of Directors

Last updated: 2024-12-31

Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. logo
Market Cap: High
Employees: Low

EDG-5506

Edgewise Therapeutics, Inc. is a biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, including treatments for Duchenne muscular dystrophy and Becker muscular dystrophy.

Tags: Becker muscular dystrophy, Duchenne muscular dystrophy, biopharmaceutical, musculoskeletal diseases, small molecule therapies

Symbol: EWTX

Recent Price: $27.05

Industry: Biotechnology

CEO: Dr. Kevin Koch Ph.D.

Sector: Healthcare

Employees: 97

Address: 3415 Colorado Avenue, Boulder, CO 80303

Phone: 303 735 8373

Leadership

  • Kevin Koch, Ph.D., Director
  • Alan Russell, Ph.D., Director and Co-Founder
  • R. Michael Carruthers, Chief Financial Officer
  • Behrad Derakhshan, Ph.D., Chief Business Officer
  • Joanne M. Donovan, M.D., Ph.D., Chief Medical Officer
  • John Moore, General Counsel
  • Marc Semigran, M.D., Chief Development Officer
  • Peter Thompson, M.D., Chairman and Co-Founder
  • Laura Brege, Director
  • Badreddin Edris, Ph.D., Director and Co-Founder
  • Jonathan C. Fox, M.D., Ph.D., FACC, Director
  • Arlene Morris, Director
  • Jon Root, M.D., Director

Last updated: 2024-12-31

EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

EGP-437

Eye Gate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye.

Tags: EGP-437, clinical stage, drug delivery, eye diseases, pharmaceutical, uveitis

Symbol: EYEG

Recent Price: $35.04

Industry: Biotechnology

CEO: Mr. Stephen From

Sector: Healthcare

Employees: 14

Address: 271 Waverley Oaks Rd Ste 108, Waltham, MASSACHUSETTS 02452

Phone: 17817889043

Leadership

  • Paul Chaney, Chairman of the Board
  • Morton F. Goldberg, MD, Director
  • Praveen Tyle, PhD, Director
  • Thomas Balland, Director
  • Thomas E. Hancock, Director
  • Bernard Malfroy-Camine, PhD, Director
  • Mounia Chaoui, PhD, Director

Last updated: 2024-12-31

Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

KPI-012, EYSUVIS, INVELTYS

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases using proprietary mucus penetrating particles technology.

Tags: biopharmaceutical, corneal epithelial defects, dry eye disease, eye diseases, gene expression, mucus penetrating particles, ocular surgery, retinal diseases

Symbol: KALA

Recent Price: $6.87

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Mark T. Iwicki

Sector: Healthcare

Employees: 43

Address: 1167 Massachusetts Avenue, Arlington, MA 02476

Phone: 781 996 5252

Last updated: 2024-12-31

PepGen Inc.

PepGen Inc. logo
Market Cap: Low
Employees: Low

PGN-EDO51

Pep Gen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for neuromuscular and neurologic diseases. Its lead product, PGN-EDO51, is in Phase I trials for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, biotechnology, clinical trials, neuromuscular diseases, oligonucleotide therapeutics

Symbol: PEPG

Recent Price: $3.83

Industry: Biotechnology

CEO: Dr. James G. McArthur Ph.D.

Sector: Healthcare

Employees: 72

Address: 245 Main Street, Cambridge, MA 02142

Phone: 781-797-0979

Last updated: 2024-12-31

Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

ENTR-601-44

Entrada Therapeutics, Inc. develops endosomal escape vehicle (EEV) therapeutics for treating neuromuscular diseases, with a lead product candidate ENTR-601-44 in preclinical trials for Duchenne muscular dystrophy and myotonic dystrophy type 1.

Tags: Duchenne muscular dystrophy, EEV therapeutics, biotechnology, myotonic dystrophy type 1, neuromuscular diseases

Symbol: TRDA

Recent Price: $17.37

Industry: Biotechnology

CEO: Mr. Dipal Doshi

Sector: Healthcare

Employees: 168

Address: 6 Tide Street, Boston, MA 02210

Phone: 857 520 9158

Last updated: 2024-12-31

EastGroup Properties, Inc.

EastGroup Properties, Inc. logo
Market Cap: Highest
Employees: Low

Industrial Properties

East Group Properties, Inc. (NYSE: EGP) is a self-administered equity real estate investment trust specializing in the development, acquisition, and operation of industrial properties. Focused on major Sunbelt markets in the U.S., it aims to maximize shareholder value by owning and managing functional, flexible, and quality business distribution spaces. The company holds approximately 60.5 million square feet of real estate, with an emphasis on facilities near major transportation features.

Tags: Distribution Facilities, Industrial Properties, Investment Trust, Real Estate, Sunbelt Markets

Symbol: EGP

Recent Price: $161.13

Industry: REIT - Industrial

CEO: Mr. Marshall A. Loeb

Sector: Real Estate

Employees: 95

Address: 400 West Parkway Place, Ridgeland, MS 39157

Phone: 601-354-3555

Leadership

  • Marshall A. Loeb,
  • Brent W. Wood, Executive Vice President & Chief Financial Officer
  • John F. Coleman, Executive Vice President
  • Ryan M. Collins, Senior Vice President
  • R. Reid Dunbar, Senior Vice President
  • Staci H. Tyler, CPA, Senior Vice President, Chief Accounting Officer & Chief Administrative Officer
  • Barry T. Anderson, CPA, Vice President
  • Whitney Denham, CPA, Vice President
  • William D. Gray, CPA, Vice President
  • David Y. Hicks, Jr., Vice President
  • Todd Johnson, Vice President
  • Farrah Kennedy, CPA, Vice President
  • Brian Laird, CPA, Chief Information Officer
  • Ceejaye Peters, Vice President and Corporate Counsel
  • John I. Ratliff, Vice President
  • Michelle Rayner, CPA, Vice President
  • Michael P. Sacco, Vice President
  • Kevin M. Sager, Vice President
  • Stephanie Shaw, CPA, Vice President
  • John E. Travis, Vice President
  • Shelby Trusty, Vice President
  • Donald F. Colleran, Chairman of the Board
  • D. Pike Aloian,
  • H. Eric Bolton, Jr.,
  • David M. Fields,
  • Mary E. McCormick,
  • Katherine M. Sandstrom,

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. logo
Market Cap: High
Employees: Medium

AG10, BBP-265, BBP-831, BBP-631, Encaleret

Bridge Bio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases, with a pipeline of 30 programs including candidates like AG10, BBP-265, and others in various stages of clinical trials.

Tags: biopharmaceuticals, clinical trials, drug development, genetic diseases

Symbol: BBIO

Recent Price: $27.32

Industry: Biotechnology

CEO: Dr. Neil Kumar Ph.D.

Sector: Healthcare

Employees: 550

Address: 421 Kipling Street, Palo Alto, CA 94301

Phone: 650 391 9740

Last updated: 2024-12-31

Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Low

Ryanodex, Belrapzo, Bendeka, EP-4104, PEMFEXY, EA-114, Vasopressin

Eagle Pharmaceuticals, Inc. specializes in the development and commercialization of pharmaceutical products targeting diseases of the central nervous system, metabolic critical care, and oncology in the U.S. Notable products include Ryanodex for malignant hyperthermia, and oncology treatments Belrapzo and Bendeka.

Tags: antitoxin, central nervous system, collaboration agreements, critical care, disease treatment, oncology, pharmaceutical

Symbol: EGRX

Recent Price: $0.50

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Michael Graves

Sector: Healthcare

Employees: 134

Address: 50 Tice Boulevard, Woodcliff Lake, NJ 07677

Phone: 201 326 5300

Last updated: 2024-12-31

MeiraGTx Holdings plc

MeiraGTx Holdings plc logo
Market Cap: Low
Employees: Medium

Gene Therapy Treatments

Meira GTx Holdings plc is a clinical stage gene therapy company developing treatments for serious diseases, including ocular diseases, xerostomia, and neurodegenerative conditions. They are in various stages of clinical development for several gene therapy programs and have a research collaboration with Janssen Pharmaceuticals.

Tags: Clinical Stage, Gene Therapy, Neurodegenerative Diseases, Ocular Diseases, Research Collaboration, Xerostomia

Symbol: MGTX

Recent Price: $5.89

Industry: Biotechnology

CEO: Dr. Alexandria Forbes Ph.D.

Sector: Healthcare

Employees: 387

Address: 430 East 29th Street, New York, NY 10016

Phone: 646 860 7985

Leadership

  • Alexandria Forbes, Ph.D., Board Member, President and Chief Executive Officer
  • Richard Giroux, Chief Operating Officer and Chief Financial Officer
  • Stuart Naylor, Ph.D., Chief Development Officer
  • Robert K. Zeldin, M.D., Chief Medical Officer
  • Robert Wollin, JD, General Counsel and Secretary
  • Alastair Leighton, Ph.D, SVP, Manufacturing and Supply Chain
  • Christine Sheehy, SVP, Global Integration
  • Tim Randall, SVP, Risk and Internal Controls
  • Michel Michaelides, M.D., Head of Clinical Ophthalmology
  • Tassos Georgiadis, Ph.D., Vice President, Preclinical Development
  • Keith R. Harris, Ph.D., Chairman of the Board
  • Ellen Hukkelhoven, Ph.D., Board Member
  • Lord Mendoza, Independent Board Member
  • Nicole Seligman, Independent Board Member
  • Thomas E. Shenk, Ph.D., Independent Board Member
  • Debra Yu, M.D., Independent Board Member

Last updated: 2024-12-31

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

STK-001, STK-002

Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing antisense oligonucleotide medicines to treat genetic diseases. Their lead product, STK-001, is aimed at treating Dravet syndrome, while STK-002 targets autosomal dominant optic atrophy.

Tags: Dravet syndrome, antisense oligonucleotides, biopharmaceutical, epilepsy, genetic diseases, genetic medicine

Symbol: STOK

Recent Price: $10.80

Industry: Biotechnology

CEO: Dr. Edward M. Kaye M.D., Ph.D.

Sector: Healthcare

Employees: 110

Address: 45 Wiggins Avenue, Bedford, MA 01730

Phone: 781 430 8200

Leadership

  • Edward M. Kaye, M.D., Chief Executive Officer & Director
  • Jonathan Allan, J.D., General Counsel
  • Isabel Aznarez, Ph.D., Senior Vice President, Discovery Research and Co-Founder
  • Jason Hoitt, Chief Commercial Officer
  • Dawn Kalmar, Chief Communications Officer
  • Tommy Leggett, Chief Financial Officer
  • Shamim Ruff, Chief Regulatory Officer
  • Barry S. Ticho, M.D., Ph.D., FACC, Chief Medical Officer
  • Joan Wood, Chief Human Resources Officer
  • Adrian Krainer, Ph.D., Co-founder & Director
  • Arthur Tzianabos, Ph.D., Chairman
  • Jennifer Burstein, MBA, CPA, Director
  • Seth L. Harrison, M.D., Director
  • Arthur Levin, Ph.D., Director
  • Garry E. Menzel, Ph.D., MBA, Director
  • Ian F. Smith, Director
  • Julie Anne Smith, Director

Last updated: 2024-12-31